Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments

NCT ID: NCT05927688

Last Updated: 2025-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

352 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-18

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher risk of cardiovascular diseases. To this end, the general treat-to-target approach, as recommended in the EULAR guidance, may require several successive treatment lines based on updates to the patients' profile and close monitoring as the keystone of its implementation.

Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email when a patient has completed a form (no data interpretation or alerts).

The hypothesis is that the more physicians are provided with insights into their patients' health, the more they will function in a treat-to-target approach and the more often they will tend to adjust their patients' treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gout Rheumatoid Arthritis Sjogren's Syndrome Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients whose physician used the electronic platform to access ePRO

Therapeutic management following access by the physician to his patient's ePROs

Intervention Type BEHAVIORAL

Therapeutic management following access by the physician to his patient's ePROs

Patients whose physician did not used the electronic platform and did not access ePRO

Therapeutic management following access by the physician to his patient's ePROs

Intervention Type BEHAVIORAL

Therapeutic management following access by the physician to his patient's ePROs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Therapeutic management following access by the physician to his patient's ePROs

Therapeutic management following access by the physician to his patient's ePROs

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women of at least 18 years of age
* Diagnosed with (at least) one of the following autoimmune diseases:

* Rheumatoid arthritis (RA) according to the 2010 EULAR/ACR classification criteria,
* Gout according to the 2015 EULAR/ACR classification criteria,
* Systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria
* Sjogren's Syndrome according to the 2016 EULAR/ACR classification criteria
* According to local regulations, patient has expressed his/her non-opposition (for France) or has provided written informed consent (for Switzerland and Germany) to participate in the study
* Patient has access to the internet, a functioning email address and a mobile phone number
* Patient physically and mentally able to use a computer tool connected to the Internet
* Only in Switzerland \& Germany : patient is covered by a health insurance plan

Exclusion Criteria

* Any neurodegenerative disease that alters cognitive faculties
* Refractory cancer
* Patients who do not have access to the Internet and/or do not master its use in the context of this protocol
* Unwillingness or inability to adhere to study protocol (language barriers, cognitive disorders…) Subject who is compulsorily detained for psychiatric treatment
* Patient who cannot be followed for 2 years by the investigating physician
* Patient over the age of legal majority who is protected, or deprived of liberty by judicial or administrative decision (vulnerable subject)
* Patient with an estimated life expectancy shorter than 1 year
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Strasbourg

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jacques-Eric GOTTENBERG, Professor

Role: CONTACT

3 88 12 79 53 ext. +33

Jacques-Eric GOTTENBERG, MD, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jacques-Eric GOTTENBERG, MD, PhD

Role: primary

3 88 12 79 53 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8546

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.